Beam Therapeutics (BEAM) Director Mark Fishman Receives Award

What Happened Mark Fishman, a director of Beam Therapeutics, was granted 19,676 derivative securities (recorded at $0.00) on June 3, 2026. The filing lists this as an award/grant (transaction code A), not a purchase or sale, so there was no cash exchanged in the reported transaction.

Key Details

• Transaction date: 2026-06-03; filing date: 2026-06-05 (filed within the standard Form 4 reporting window).
• Instrument: Award/grant of 19,676 derivative shares (listed at $0.00 in the filing).
• Shares owned after transaction: Not specified in the provided filing details.
• Footnote: Vesting — the award vests in full on the earlier of the first anniversary of the grant or immediately prior to the next annual meeting, subject to continued service on the board (Footnote F1).
• No 10b5-1 plan, cashless exercise, tax withholding, or sale was reported in the provided details.

Context This is a standard director compensation grant, recorded as a derivative award. Such grants are typically part of board compensation and do not by themselves signal an immediate buy or sell of stock on the open market. The vesting conditions mean the award becomes realizable only if Fishman remains on the board through the vesting date.